TB-500 (Thymosin Beta-4 Acetate)
All information below is drawn from preclinical research literature and is provided for educational and informational purposes only. It does not constitute medical advice, imply therapeutic outcomes, or endorse any specific application.
Chemical Identification
Property
Value
Overview
General Research Context
Thymosin Beta-4 (TB-500) is a 43-amino acid peptide that is ubiquitously expressed across mammalian tissues. It was originally identified as a component of thymic extracts. In laboratory research, TB-500 has been studied for its interactions with the intracellular actin cytoskeleton and its role in cellular motility assays.
TB-500 is classified as an actin-sequestering peptide and has been examined across multiple preclinical model systems, including those involving endothelial cell migration and connective tissue remodeling. The compound remains an investigational research tool without regulatory approval for any clinical application.
Areas of Investigation
Observed Interactions and Background
In cell culture models, TB-500 has been observed to bind G-actin monomers, an interaction associated with changes in actin polymerization dynamics. Published literature has described its involvement in cellular migration assays, where researchers noted alterations in lamellipodial formation and directional cell movement.
Preclinical transcriptomic analyses have reported that TB-500 interacts with pathways associated with integrin signaling and extracellular matrix composition. Separate in vitro studies have examined the compound in the context of vascular endothelial growth factor (VEGF) expression and angiogenic pathway markers in isolated tissue models. These observations are limited to preclinical research settings.
Laboratory Notes
Synthesis and Stability Notes
TB-500 is synthesized utilizing highly complex, multi-step solid-phase peptide synthesis protocols due to its substantial length of 43 amino acids. As a highly hydrophilic and physically massive macromolecule, the resulting lyophilized powder must be reconstituted with extreme care. Due to its size and inherent structural flexibility, it is significantly more susceptible to physical degradation via aggressive mechanical agitation (shearing) and thermal degradation when compared to shorter peptides like BPC-157. Thus, stringent cold storage protocols, typically involving -20°C environments, are strictly required for long-term laboratory preservation to prevent spontaneous aggregation or oxidative damage to the sequence.
Disclaimer: All information provided herein is strictly for educational and laboratory research reference purposes only. Saga does not endorse, interpret, or evaluate these preclinical studies for any specific in vivo application or human therapeutic outcome.